• Je něco špatně v tomto záznamu ?

Citrate anticoagulation control by ionized calcium levels does not prevent hemostasis and complement activation during hemodialysis

Opatrný K, Richtrová P, Polanská K, Wirth J, Sefrna F, Brandl M, Falkenhagen D

. 2007 ; 31 (3) : 200-207.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky

Perzistentní odkaz   https://www.medvik.cz/link/bmc07527922
E-zdroje Online

NLK Medline Complete (EBSCOhost) od 1998-01-01 do Před 1 rokem
Wiley Online Library (archiv) od 1997-01-01 do 2012-12-31

The purpose of this study was to determine whether or not regional citrate anticoagulation (RCA) controlled by ionized calcium (iCa(2+)) would overcome thrombogenicity, prevent hemostasis, and complement activation during hemodialysis (HD). RCA was performed in 10 patients during 10 HD sessions using a polysulfone membrane in an effort to keep iCa(2+) at dialyzer outlet at < or =0.4 mmol/L. Compared to baseline, plasma levels of thrombin-antithrombin III complexes rose significantly at 240 min, and tissue factor and complement C5a component levels at 30 and 240 min of the procedure. Thrombocyte count declined significantly at 30 and 240 min, while activated clotting time (ACT) did not increase significantly, and platelet factor 4 as well as von Willebrand factor levels did not alter significantly. While ACT correlated significantly with some thrombogenicity markers, iCa(2+) did not correlate with ACT, changes in hemostasis, or C5a. We conclude the usually recommended iCa(2+) levels in the HD extracorporeal circuit did not guarantee the complete overcoming of thrombogenicity, prevention of hemostasis, and complement activation.

000      
00000naa 2200000 a 4500
001      
bmc07527922
003      
CZ-PrNML
005      
20250121143652.0
008      
090830s2007 xxu e eng||
009      
AR
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Opatrný, Karel, $d 1954-2006 $7 nlk19990073633
245    10
$a Citrate anticoagulation control by ionized calcium levels does not prevent hemostasis and complement activation during hemodialysis / $c Opatrný K, Richtrová P, Polanská K, Wirth J, Sefrna F, Brandl M, Falkenhagen D
314    __
$a Department of Internal Medicine I, Charles University Medical School, Alej Svobody 80, 304-60 Pilsen, Czech Republic
520    9_
$a The purpose of this study was to determine whether or not regional citrate anticoagulation (RCA) controlled by ionized calcium (iCa(2+)) would overcome thrombogenicity, prevent hemostasis, and complement activation during hemodialysis (HD). RCA was performed in 10 patients during 10 HD sessions using a polysulfone membrane in an effort to keep iCa(2+) at dialyzer outlet at < or =0.4 mmol/L. Compared to baseline, plasma levels of thrombin-antithrombin III complexes rose significantly at 240 min, and tissue factor and complement C5a component levels at 30 and 240 min of the procedure. Thrombocyte count declined significantly at 30 and 240 min, while activated clotting time (ACT) did not increase significantly, and platelet factor 4 as well as von Willebrand factor levels did not alter significantly. While ACT correlated significantly with some thrombogenicity markers, iCa(2+) did not correlate with ACT, changes in hemostasis, or C5a. We conclude the usually recommended iCa(2+) levels in the HD extracorporeal circuit did not guarantee the complete overcoming of thrombogenicity, prevention of hemostasis, and complement activation.
650    _2
$a financování organizované $7 D005381
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a antikoagulancia $x farmakologie $7 D000925
650    _2
$a hemokoagulace $x účinky léků $7 D001777
650    _2
$a vápník $x krev $x terapeutické užití $7 D002118
650    _2
$a citráty $x farmakologie $7 D002951
650    _2
$a aktivace komplementu $x účinky léků $7 D003167
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a počet leukocytů $7 D007958
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a aktivace trombocytů $x účinky léků $7 D015539
650    _2
$a dialýza ledvin $7 D006435
650    _2
$a trombóza $x prevence a kontrola $7 D013927
655    _2
$a klinické zkoušky $7 D016430
700    1_
$a Richtrová, Pavlína, $d 1975- $7 xx0074467
700    1_
$a Polanská, Kamila $7 xx0098547
700    1_
$a Wirth, Jan $7 xx0123183
700    1_
$a Šefrna, František $7 xx0179993
700    1_
$a Brandl, Martin $7 xx0327927
700    1_
$a Falkenhagen, Dieter, $d 1942-2015 $7 xx0215077
773    0_
$w MED00000595 $t Artificial organs $g Roč. 31, č. 3 (2007), s. 200-207 $x 0160-564X
910    __
$a ABA008 $b x $y 9 $z 0
990    __
$a 20090824163150 $b ABA008
991    __
$a 20250121143648 $b ABA008
999    __
$a ok $b bmc $g 672952 $s 532197
BAS    __
$a 3
BMC    __
$a 2007 $b 31 $c 3 $d 200-207 $i 0160-564X $m Artificial organs $x MED00000595
LZP    __
$a 2009-B4/vtme

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...